

Prevention Of Hypertensive Injury to the Brain by Intensive Treatment in IntraCerebral Haemorrhage

PR HIBIT-ICH ·))

David Werring Professor of Clinical Neurology UCL Queen Square Institute of Neurology, National Hospital for Neurology and Neurosurgery, London











# **Study sites**

Â	ſ				
		_		_	

Principal Investigators and Site Coordinators	Site
Professor David Werring Site coordinator: Nina Francia	University College Hospital, London
Professor Peter Rothwell Site coordinator: Michelle Wilson	John Radcliffe Hospital, Oxford
Dr Soma Banerjee Site coordinator: Vaishali Dave	Charing Cross Hospital, London
Professor Rustam Al-Shahi Salman Site coordinator: Allan MacRaild	Royal Infirmary of Edinburgh
Dr Adrian Parry-Jones Site coordinator: Stephanie Lee	Salford Royal Hospital, Manchester
Professor Hedley Emsley Site coordinator: Bindu Gregary	Royal Preston Hospital
Dr Dulka Manawadu Site coordinator: Con Tibajia	Kings College Hospital, London
Dr Niamh Hannon Site coordinator: Sarah Finlay	Addenbrooke's Hospital, Cambridge
Dr Kailash Krishnan Site coordinator: Benjamin Jackson	Nottingham University Hospitals NHS Trust
Dr Keith Muir Site coordinator: Angela Welch	Queen Elizabeth University Hospital, Glasgow
Dr Liqun Zhang Site coordinator: Rita Ghatala	St George's Hospital, London
Dr Kirsty Harkness Site coordinator: Christine Kamara	Sheffield Teaching Hospitals NHS Foundation Trust











#### **Study teams**

Royal Infirmary of Edinburgh



Queen Elizabeth University Hospital, Glasgow



Charing Cross Hospital, London

Salford Royal Hospital, Manchester



University College Hospital, London





Addenbrooke's Hospital, Cambridge





St George's Hospital, London







- 1. Trial overview
- 2. Recruitment
- 3. Amendments
- 4. Data report
- 5. Proposed changes













Prevention Of Hypertensive Injury to the Brain by Intensive Treatment in IntraCerebral Haemorrhage

PROHIBIT-ICH is a pilot multi-site randomised controlled trial comparing a strategy of intensive BP treatment (target <120/80 mm Hg) guided by telemetric home monitoring versus standard care in 112 adult ICH survivors

#### **Objectives**

- To assess the feasibility of intensive BP treatment using centralised telemetric home monitoring in a multi-centre setting in patients with previous ICH
- To investigate whether intensive BP treatment through the home monitoring device results in a reduction in the progression of small vessel related brain injury assessed on MRI compared with standard BP treatment









## **Basic trial structure**







Where are we now?



Total number of participants recruited	46 participants (41% of target)	Total target number of participants for trial	112 participants
Total duration of recruitment to date	15 months (50% of full duration)	Planned duration of recruitment (revised)	28 months
Start date of recruitment	11 March 2019	Current predicted recruitment end date	31 December 2021
Start date of COVID-19 lockdown pause	20 March 2020	End date of COVID- 19 lockdown pause	8 July 2020









#### Site recruitment



Sites	Participants recruited	Months site active	Recruitment rate per month
Kings College Hospital, London	7	11	0.6
Addenbrooke's Hospital, Cambridge	8	16	0.4
University College Hospital, London	5	15	0.3
Royal Infirmary of Edinburgh	5	16	0.3
St George's Hospital, London	4	12	0.3
John Radcliffe Hospital, Oxford	4	16	0.3
Sheffield Teaching Hospitals NHS Foundation Trust	3	12	0.3
Nottingham University Hospitals NHS Trust	3	12	0.3
Queen Elizabeth University Hospital, Glasgow	3	16	0.2
Charing Cross Hospital, London	3	12	0.3
Salford Royal Hospital, Manchester	1	12	0.08
Royal Preston Hospital	0	12	0
TOTAL NUMBER RECRUITED	46	13.5	Mean=0.3
	PSITY OF		EL L









## Where do we need to get to?



**Revised per site recruitment rate of 0.4 participants per month** (current recruitment rate is 0.3 per month)









#### Data completeness



	Baseline	3-month follow-up	12-month follow-up
Patients with complete clinical data, n/total assessed (%)	43/43 (100%)	33/35 (94.3%)	7/20 (35.0%)
Patients with complete assessment BP data, n/total assessed (%)	43/43 (100%)	33/35 (94.3%)	7/20 (35.0%)
Patients with complete ABPM data, n/total assessed (%)	35/43 (81.0%)	29/35 (82.9%)	7/10 (70.0%)

Assessment	Number of participants	Contingency measures taken
3-month follow-up	3	No 3-month assessment BP; two ABPM test readings used in lieu
12-month follow-up	13	Follow-up postponed







# PROHIBIT-ICH MRI quality outcome 🛓 🛛 🗲

#1+	1040101010		20.74		-		-		
Site	Scan no	Scans Received	3D T1	3D FLAIR	DTI	3D SWI	AXIAL T2	ASL	<u> </u>
UCLH	10XX	5	100% (5/5)	100% (5/5)	100% (5/5)	100% (5/5)	100% (5/5)	100% (5/5)	6001 - DTI unuser
Imperial	60XX	2	100% (2/2)	100% (2/2)	100% (2/2)	100% (2/2)	100% (2/2)	100% (2/2)	done!
St George's	120XX	4	100% (4/4)	100% (4/4)	100% (4/4)	100% (4/4)	100% (4/4)	100% (4/4)	12003 - minor problem 12004 - 3D FLAIR (a bit motion volumed); DTI (top of brain is missing)
Oxford	20XX	2	100% (2/2)	100% (2/2)	50% (1/2)	100% (2/2)	100% (2/2)	100% (2/2)	2002 - Had claustrophobia; 2003 - DTI not available at the time of scanning
Glasgow	50XX	3	67% (2/3)	67% (2/3)	67% (2/3)	33% (1/3)	67% (2/3)	33% (1/3)	5002 - Not to protocol. Asked to rescan. Can still be manually analysed; 3D T1 - not isotropic; 3D FLAIR - not isotropic; DTI - missing; 3D SWI - not isotropic; AXIAL T2 - not to protocol; 5003 - Pt terminated scan, movement
Sheffield	110XX	3	100% (3/3)	100% (3/3)	100% (3/3)	100% (3/3)	100% (3/3)	100% (3/3)	11002 - distortion of SWI in frontal lobes, likely useable data, checked
Edinburgh	40XX	4	100% (4/4)	100% (4/4)	100% (4/4)	100% (4/4)	100% (4/4)	100% (4/4)	
Nottingham	90XX	3	100% (3/3)	0% (0/3)	100% (3/3)	100% (3/3)	100% (3/3)	0% (0/3)	9001-9003 - Midline artefact and missing lat temp lobes on the FLAIR, checked
King's	70XX	6	100% (6/6)	100% (6/6)	100% (6/6)	100% (6/6)	100% (6/6)	100% (6/6)	7002 - mild motion artefact swi, djw checked
Cambridge	30XX	5	100% (5/5)	100% (5/5)	100% (5/5)	100% (5/5)	100% (5/5)	100% (5/5)	
Total		37	97% (36/37)	89% (33/37)	95% (35/37)	95% (35/37)	97% (36/37)	86% (32/37)	

Please follow the instructions in the PROHIBIT-ICH imaging manual and ensure that all follow-up scans are done according to the same protocol and on the same scanner!









- Patients can be recruited if not discharged home
- Age limit lowered to ≥30 years
- Patients can also be identified from site databases and contacted by email or post
- Posters to be displayed at participating sites
- Patient Identification Centre (PIC) sites
- Invite four new sites to participate in the study











- Three sites in set-up
  - Royal Devon and Exeter Hospital
  - Sandwell and West Birmingham
  - Leeds teaching hospital NHS trust











Recruiting/research site	NHS PIC sites
UCLH	<ol> <li>Barnet, Royal Free</li> <li>North Middlesex</li> </ol>
John Radcliffe Hospital, Oxford	<ol> <li>Swindon's Great Weston Hospital</li> <li>Stoke Mandeville Hospital in Aylesbury.</li> <li>Reading Royal Berkshire Hospital</li> </ol>
Addenbrooke's Hospital, Cambridge	<ol> <li>West Suffolk</li> <li>Peterborough -Temple</li> <li>Hinchingbrooke</li> </ol>
Salford Royal Hospital	<ol> <li>Stepping Hill Hospital in Stockport</li> <li>Fairfield Hospital at Pennine Acute</li> </ol>
Sheffield Teaching Hospitals NHS Trust	1. Doncaster Royal Infirmary
St George's Hospital	<ol> <li>Croydon University hospital</li> <li>Epsom and St.Helier Hospital</li> <li>Kingston Hospital.</li> </ol>









- Continue usual follow-up of all recruited participants including BP at 3 months and MRI at 12 months (can be delayed until MRI is available)
- Plan to recruit 60 participants with research MRI at sites which can do this
- But allow the use of a standard clinical MRI instead of a research MRI
- For participants in whom MRI is contraindicated or not possible we propose to allow recruitment without MRI (as long as the qualifying ICH is confirmed by a CT scan)









#### **PROHIBIT-ICH TEAM**



Co-Chief Investigator (UCL)	Professor David Werring
	d.werring@ucl.ac.uk
Co-Chief Investigator (Oxford)	Professor Peter Rothwell
	peter.rothwell@ndcn.ox.ac.uk
Trial Coordinators (UCL)	Shahena Butt (until Jan 2021)
	shahena.butt@ucl.ac.uk
	Tel: 0203 108 6181
	Maja Dabagh
	m.dabagh@ucl.ac.uk
<b>Clinical Research Practitioner:</b>	Michelle Wilson
(Oxford)	michelle.wilson@ndcn.ox.ac.uk
	Tel: 01865 231601
BP Research Coordinator:	Louise Silver
(Oxford)	louise.silver@ndcn.ox.ac.uk
	Tel: 01865 234622
<b>BP Clinical Research Fellow:</b>	lain McGurgan
(Oxford)	ian.mcgurgan@ndcn.ox.ac.uk
	Tel: 01865 231601











Trial Coordinators	Maja Dabagh <u>m.dabagh@ucl.ac.uk</u> Shahena Butt <u>shahena.butt@ucl.ac.uk</u> Tel: 0203 108 6181
Neuroradiologist	Professor Rolf Jager r.jager@ucl.ac.uk
Neuroradiologist	Professor Frederik Barkhof <u>f.barkhof@ucl.ac.uk</u>
Physicist	Dr David Thomas d.thomas@ucl.ac.uk













Prevention Of Hypertensive Injury to the Brain by Intensive Treatment in IntraCerebral Haemorrhage





#### Website:

https://www.ndcn.ox.ac.uk/research/prohibit-ich-project

Email:

m.dabagh@ucl.ac.uk





